Faricimab 是一种针对血管生成素-2 和血管内皮生长因子- A 的双特异性抗体，具有良好的安全性和耐受性。Faricimab 在视网膜缺血/再灌注 损伤和 sCNV 小鼠模型中可预防视网膜血管渗漏、细胞死亡和炎症。与 Ranibizumab 相比，Faricimab 在统计学上显示出更好的视力改善。Faricimab 可用于视网膜疾病研究，如年龄相关性黄斑变性，糖尿病性黄斑水肿 和视网膜静脉阻塞后黄斑水肿。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The purity of Anti-ANG2 & VEGFA Reference Antibody (Faricimab) is more than 95%, determined by SEC-HPLC.

Immobilized VEGFA Protein at 2 μg/mL can bind Anti-ANG2 & VEGFA Reference Antibody (Faricimab).

Affinity constant of 1.25E-10M as determined in BLI assay.（Human ANGPT2, His Tag）

Anti-ANG2 & VEGFA Reference Antibody (Faricimab)-Proliferation inhibition using HUVEC Cell. The maximum proliferation inhibition rate is about 80%

Anti-ANG2 & VEGFA Reference Antibody (Faricimab) Luciferase Assay was evaluated using VEGFR2-NF-AT HEK293 Cell. The IC50 was approximately 8.449 nM .

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.